4 research outputs found
Arag贸n educa : revista del Museo Pedag贸gico de Arag贸n
Se habla de las actividades y pr谩cticas llevadas a cabo en el Centro de Arte y Naturaleza de la Fundaci贸n Beulas de Huesca. Se explican las acciones llevadas a cabo en el centro y fuera de 茅l para la promoci贸n y conocimiento de dos de sus colecciones: Beaulas-Serrate y arte y naturaleza.Arag贸nDirecci贸n General de Pol铆tica Educativa; Avda. G贸mez Laguna, 25, planta 2; 50009 Zaragoza; Tel. +34976715416; Fax +34976715496ES
Arag贸n educa : revista del Museo Pedag贸gico de Arag贸n
Se habla del desarrollo creciente de la funci贸n educativa en los museos de Arag贸n. Se evidencia el acercamiento del patrimonio cultural que ofrecen, sirviendo de apoyo en el desarrollo curricular de diversas materias. Se resumen las actividades, los talleres, las exposiciones y las visitas guiadas que se ofrecen en los museos m谩s importantes de Arag贸n. Se destaca el aumento de las exigencias de calidad de sus usuarios debido a la extensi贸n de los medios audiovisuales, las tecnolog铆as de la informaci贸n y de la comunicaci贸n.Arag贸nDirecci贸n General de Pol铆tica Educativa; Avda. G贸mez Laguna, 25, planta 2; 50009 Zaragoza; Tel. +34976715416; Fax +34976715496ES
DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf
BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome.ParticipantsPatients admitted due to COVID-19 infection with mild disease.ResultsUp to 92 were included. Mean age was 64 卤 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy.ConclusionsRuxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration.Trial registrationhttps://clinicaltrials.gov/, identifier NCT04348695.</p
Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx
BackgroundManaging the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.MethodsWe designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19. 48 cytokines were correlated with clinical outcome.ParticipantsPatients admitted due to COVID-19 infection with mild disease.ResultsUp to 92 were included. Mean age was 64 卤 17, and 28 (30%) were female. 11 (22%) patients in the control arm and 6 (12%) in the experimental arm reached an OSCI grade of 5 or higher (p = 0.29). Unsupervised analysis of cytokines detected two clusters (CL-1 and CL-2). CL-1 presented a higher risk of clinical deterioration vs CL-2 (13 [33%] vs 2 [6%] cases, p = 0.009) and death (5 [11%] vs 0 cases, p = 0.059). Supervised Machine Learning (ML) analysis led to a model that predicted patient deterioration 48h before occurrence with a 85% accuracy.ConclusionsRuxolitinib plus simvastatin did not impact the outcome of COVID-19. Cytokine profiling identified patients at risk of severe COVID-19 and predicted clinical deterioration.Trial registrationhttps://clinicaltrials.gov/, identifier NCT04348695.</p